Drug
Tafasitamab
Tafasitamab: highest development phase Phase 3, developed by Incyte, InnoCare Pharma. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Incyte, InnoCare Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tafasitamab NCT04824092 | Phase 3 | Diffuse Large B-cell Lymphoma |
| tafasitamab NCT04680052 | Phase 3 | Follicular Lymphoma |
| Tafasitamab NCT05429268 | Phase 3 | Large B-Cell Lymphoma |
| Tafasitamab NCT06521255 | Phase 3 | DLBCL |
| Tafasitamab NCT07502872 | Phase 2 | Diffuse Large B Cell Lymphoma |
Latest
No recent events.
Follow Tafasitamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.